Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Zaimi

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|June 20, 2024
Current therapeutic approach of chronic kidney disease-mineral and bone disorderMaria Zaimi, Eirini Grapsa
Annual Review of Pharmacology and Toxicology|September 18, 2023
Novel Immunopharmacological Drugs for the Treatment of Allergic DiseasesEkaterini Tiligada, Daria Gafarov, Maria Zaimi, et al.
Journal of Clinical Medicine|January 28, 2026
Gene Expression as a Guide for the Development of Novel Therapies in Hypertensive and Diabetic Kidney DiseaseMaria Zaimi, Georgios Zagkotsis, Athanasios Kammenos, et al.
Pharmacological Research|October 15, 2022
Glucocorticoids and COVID-19Stefano Bruscoli, Pier Giorgio Puzzovio, Maria Zaimi, et al.
Endocrine|February 14, 2024
Gonadal dysfunction in women with diabetes mellitusMaria Zaimi, Olympia Michalopoulou, Katerina Stefanaki, et al.
International Journal of Dermatology|July 25, 2024
Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areasNatalia Rompoti, Theognosia Vergou, Irene Stefanaki, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 20, 2024
Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasisNatalia Rompoti, Irene Stefanaki, Pantelis Panagakis, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|June 20, 2024
Current therapeutic approach of chronic kidney disease-mineral and bone disorderMaria Zaimi, Eirini Grapsa
Annual Review of Pharmacology and Toxicology|September 18, 2023
Novel Immunopharmacological Drugs for the Treatment of Allergic DiseasesEkaterini Tiligada, Daria Gafarov, Maria Zaimi, et al.
Journal of Clinical Medicine|January 28, 2026
Gene Expression as a Guide for the Development of Novel Therapies in Hypertensive and Diabetic Kidney DiseaseMaria Zaimi, Georgios Zagkotsis, Athanasios Kammenos, et al.
Pharmacological Research|October 15, 2022
Glucocorticoids and COVID-19Stefano Bruscoli, Pier Giorgio Puzzovio, Maria Zaimi, et al.
Endocrine|February 14, 2024
Gonadal dysfunction in women with diabetes mellitusMaria Zaimi, Olympia Michalopoulou, Katerina Stefanaki, et al.
International Journal of Dermatology|July 25, 2024
Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areasNatalia Rompoti, Theognosia Vergou, Irene Stefanaki, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 20, 2024
Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasisNatalia Rompoti, Irene Stefanaki, Pantelis Panagakis, et al.
Pageof 1